scispace - formally typeset
L

Laurent Castera

Researcher at University of Paris

Publications -  232
Citations -  14382

Laurent Castera is an academic researcher from University of Paris. The author has contributed to research in topics: Transient elastography & Cirrhosis. The author has an hindex of 56, co-authored 232 publications receiving 10435 citations. Previous affiliations of Laurent Castera include University of Bordeaux & University of Caen Lower Normandy.

Papers
More filters
Journal ArticleDOI

A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.

TL;DR: A panel of international experts from 22 countries propose a new definition of metabolic-dysfunction-associated fatty liver disease that is both comprehensive yet simple for the diagnosis of MAFLD and is independent of other liver diseases.
Journal ArticleDOI

Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease.

TL;DR: The current state of the noninvasive assessment of liver disease in NAFLD is summarized, and an expert synthesis of how these nonin invasive tools could be utilized in clinical practice is provided.
Journal ArticleDOI

Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial

Valérie Vilgrain, +111 more
- 01 Dec 2017 - 
TL;DR: SarAH was a multicentre, open-label, randomised, controlled, investigator-initiated, phase 3 trial done at 25 centres specialising in liver diseases in France to compare the efficacy and safety of sorafenib to that of selective internal radiotherapy in patients with hepatocellular carcinoma.
Journal ArticleDOI

EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update

TL;DR: In this article, the authors provide the latest update to the EASL Clinical Practice Guidelines on the use of non-invasive tests for the evaluation of liver disease severity and prognosis.
Journal ArticleDOI

Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk

Fergus J. Couch, +261 more
- 27 Mar 2013 - 
TL;DR: It is estimated that the breast cancer lifetime risks for the5% of BRCA1 carriers at lowest risk are 28%–50% compared to 81%–100% for the 5% at highest risk, and the ovarian cancer lifetime risk is 63% or higher, based on the known cancer risk-modifying loci.